Citations

Clear

1053 citation(s) found for "Andre, F".

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Jain, Michael D. , Spiegel, Jay Y. , Lin, Yi , Dahiya, Saurabh , Lunning, Matthew A. , Lekakis, Lazaros J. , Oluwole, Olalekan O. , Deol, Abhinav , Sehgal, Alison R. , Hill, Brian T. , Vu, Khoan , Westin, Jason R. , Cashen, Amanda F. , Rapoport, Aaron P. , Miklos, David B. , Neelapu, Sattva S. , Oluwole, Olalekan O , Miklos, David B , Jain, Michael D , Westin, Jason R , Lin, Yi , Nastoupil, Loretta J. , Feng, Lei , Ghobadi, Armin , Reagan, Patrick Michael , McGuirk, Joseph P. , Goy, Andre Henri , Andreadis, Charalambos Babis , Muñoz, Javier , Chavez, Julio C , Bennani, N. Nora , Vose, Julie M. , Locke, Frederick L.

Mayo Clinic

Journal of Clinical Oncology | May 13, 2020 | Volume: 38 | Issue: 27 | Pages: 3119-3128

10.1200/jco.19.02104 | PMID 32401634 Get It

PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed best overall and complete response rates in infused patients of 83% and 58%, respectively. We report clinical outcomes with axi-cel in the standard-of-care (SOC) setting for the approved indication. PATIENTS AND METHODS Data were collected retrospectively from all patients with relapsed/refractory LBCL who underwent leukapheresis as of September 30, 2018, at 17 US institutions with the intent to receive SOC axi-cel. Toxicities were graded and managed according to each institution’s guidelines. Responses were assessed as per Lugano 2014 classification. RESULTS Of 298 patients who underwent leukapheresis, 275 (92%) received axi-cel therapy. Compared with the registrational ZUMA-1 trial, 129 patients (43%) in this SOC study would not have met ZUMA-1 eligibility criteria because of comorbidities at the time of leukapheresis. Among the axi-cel–treated patients, grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 7% and 31%, respectively. Nonrelapse mortality was 4.4%. Best overall and complete response rates in infused patients were 82% (95% CI, 77% to 86%) and 64% (95% CI, 58% to 69%), respectively. At a median follow-up of 12.9 months from the time of CAR T-cell infusion, median progression-free survival was 8.3 months (95% CI, 6.0 to15.1 months), and median overall survival was not reached. Patients with poor Eastern Cooperative Oncology Group performance status of 2-4 and elevated lactate dehydrogenase had shorter progression-free and overall survival on univariable and multivariable analysis. CONCLUSION The safety and efficacy of axi-cel in the SOC setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.
International Organization for the Study of IBD Recommendations for Surgery in Patients With IBD During the Coronavirus Disease 2019 Pandemic
Remzi, Feza H. , Panís, Yves , Spinelli, Antonino , Mantzaris, Gerassimos J. , Söderholm, Johan D. , D’Hoore, André , Bemelman, Willem A. , Pembérton, John H., Tiret, Emmanuel , Öresland, Tom , Fleshner, Phillip , Spinelli, Antonino , Kotze, Paulo Gustavo , Yamamoto, Takayuki

Mayo Clinic

Diseases of the Colon & Rectum | April 30, 2020 | Volume: 63 | Issue: 7 | Pages: 870-873

10.1097/dcr.0000000000001718 | PMID 32355056 Get It

Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Sylte, Dillon O , Henry, Nathaniel J , LeGrand, Kate E , Abdelalim, Ahmed , Abdulkader, Rizwan Suliankatchi , Abedi, Aidin , Eshete, Akine , Abushouk, Abdelrahman Ibrahim , Adebayo, Oladimeji , Agudelo‐Botero, Marcela , Ahmad, Tauseef , Aichour, Miloud Taki Eddine, Alahdab, Fares , Alamene, Genet Melak, Alanezi, Fahad , Alebel, Animut , Alema, Niguse Meles , Ali, Beriwan Abdulqadir, Alikhani, Mahtab , Alipour, Vahid, Almasri, Nihad A. , Altirkawi, Khalid A , Amer, Yasser Sami , Amini, Saeed, Amit, Arianna Maever L. , Andrei, Cătălina Liliana , Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Ariani, Filippo , Arora, Amit , Asghari, Babak , Awoke, Nefsu , Quintanilla, Beatriz Paulina Ayala , Ayano, Getinet , Ayanore, Martin Amogre , Azari, Samad , Azarian, Ghasem , Badawi, Alaa, Badiye, Ashish , Bagli, Eleni , Baig, Atif Amin , Bairwa, Mohan , Bakhtiari, Ahad , Banach, Maciej , Banerjee, Srikanta , Banik, Palash Chandra , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Barrero, Lope H. , Barzegar, Akbar , Baye, Bayisa Abdissa , Bekuma, Tariku Tesfaye , Belete, Habte , Bennett, Derrick , Berhe, Kidanemaryam , Bhardwaj, Pankaj , Bhat, Anusha Ganapati , Bhattacharyya, Krittika , Bijani, Ali , Sayeed, Muhammad Shahdaat Bin , Borzì, Antonio Maria , Bražinová, Alexandra, Брико, Н. И. , Budhathoki, Shyam Sundar , Car, Josip , Cárdenas, Rosario , Carvalho, Félix , Castaldelli-Maia, João Maurício , Castañeda-Orjuela, Carlos A , Castelpietra, Giulio , Catalá-López, Ferrán , Cerin, Ester , Chandan, Joht Singh , Chanie, Wagaye Fentahun, Chattu, Soosanna Kumary , Chattu, Vijay Kumar , Chaudhary, Neha , Cho, Daniel , Chowdhury, Mohiuddin Ahsanul Kabir , Chu, Dinh‐Toi , Colquhoun, Samantha , Costa, Vera Marisa , Damiani, Giovanni , Dávila-Cervantes, Claudio Alberto , Demoz, Gebre Teklemariam , Demsie, Desalegn Getnet , Derakhshani, Afshin , Deribe, Kebede , Desai, Rupak , Nasab, Mostafa Dianati, Silva, Diana Dias da , Forooshani, Zahra Sadat Dibaji, Doyle, Kerrie , Driscoll, Tim , Dubljanin, Eleonora , Adema, Bereket Duko , Eagan, Arielle Wilder , Eftekhari, Aziz , Ehsani‐Chimeh, Elham , Elemineh, Demelash Abewa , El-Jaafary, Shaimaa I , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Emamian, Mohammad Hassan , Endalew, Daniel Adane , Faris, Pawan , Faro, André , Farzadfar, Farshad , Fatahi, Yousef , Fekadu, Wubalem , Ferede, Tomas Y, Fereshtehnejad, Seyed‐Mohammad , Fernandes, Eduarda , Ferrara, Pietro , Feyissa, Garumma Tolu , Fischer, Florian , Foláyan, Morẹ́nikẹ́ Oluwátóyìn , Francis, Joel M , Fukumoto, Takeshi , Geberemariyam, Biniyam Sahiledengle, Gebre, Abadi Kahsu , Gebremedhin, Ketema Bizuwork , Gebremeskel, Gebreamlak Gebremedhn , Gebremichael, Berhe , Gedefaw, Getnet , Geta, Birhanu, Ghafourifard, Mansour , Ghamari, Farhad , Ghashghaee, Ahmad , Gholamian, Asadollah , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Gubari, Mohammed Ibrahim Mohialdeen , Guo, Yuming , Haagsma, Juanita A. , Hafezi‐Nejad, Nima , Hall, Brian J. , Hamadeh, Randah R , Hasan, Md. Mehedi , Hassen, Hamid Yimam , Havmoeller, Rasmus, Heydarpour, Fatemeh , Hı́jar, Martha , Ho, Hung Chak , Hoang, Chi Linh , Hole, Michael K., Hossain, Naznin , Hosseinzadeh, Mehdi , Hostiuc, Sorin , Ibitoye, Segun Emmanuel , Ilić, Irena , Ilić, Milena , Inbaraj, Leeberk Raja , Indriasih, Endang , Irvani, Seyed Sina Naghibi , Islam, Sheikh Mohammed Shariful , Islam, M. Mofizul , Ivers, Rebecca , Jacobsen, Kathryn H. , Jahani, Mohammad Ali, Jahanmehr, Nader , Jakovljević, Mihajlo , Jayaraman, Sudha , Jha, Ravi Prakash , John-Akinola, Yetunde O. , Joseph, Nitin , Joukar, Farahnaz, Jozwiak, Jacek Jerzy , Jürisson, Mikk , Kadel, Rajendra , Kahsay, Amaha , Kalankesh, Leila R , Kalhor, Rohollah , Kamil, Teshome Abegaz, Kapoor, Neeti , Karami, Manoochehr , Kasaeian, Amir , Kassaye, Hagazi Gebremedhin, Kavetskyy, Taras , Kebede, Hafte Kahsay , Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Kelkay, Bayew, Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khalil, Ibrahim A, Khalilov, Rovshan , Khan, Ejaz Ahmad , Khan, Maseer , Khanna, Tripti, Shadmani, Fatemeh Khosravi , Khundkar, Roba , Kiirithio, Daniel N, Kim, Yun Jin , Kısa, Adnan , Kısa, Sezer , Komaki, Hamidreza , Kondlahalli, Shivakumar K M, Korshunov, Vladimir Andreevich , Kraemer, Moritz U. G. , Krishan, Kewal , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Vivek , Kumar, G Anil , Kumar, Manasi , Kumaresh, Girikumar, Kurmi, Om , Kuti, Oluwatosin, Lami, Faris , Lamichhane, Prabhat , Lang, Justin J. , Lasrado, Savita , Leasher, Janet L , Lee, Shaun Wen Huey , Lenjebo, Tsegaye Lolaso , Li, Shanshan , Linn, Shai , Liu, Xuefeng , Lunevičius, Raimundas , Lyons, Ronan A , Madadin, Mohammed , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Malagón-Rojas, Jeadran , Maled, Venkatesh , Manafi, Navid , Manafi, Amir , Manda, Ana-Laura, Mansour-Ghanaei, Fariborz, Mansouri, Borhan , March, Lyn , Mason‐Jones, Amanda J. , Masoumi, Seyedeh Zahra , Massenburg, Benjamin B. , Maulik, Pallab K , Meles, Gebrekiros Gebremichael , Melketsedik, Zeleke Aschalew , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Merie, Hayimro Edemealem , Miazgowski, Bartosz , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Mirzaei-Alavijeh, Mehdi , Mithra, Prasanna , Moazen, Babak , Moghadaszadeh, Masoud, Mohammad, Yousef , Mohammad, Karzan Abdulmuhsin , Mezerji, Naser Mohammad Gholi, Mohammadian-Hafshejani, Abdollah , Mohammadoo-Khorasani, Milad, Mohammed, Shafiu , Mohammed, Jemal , Mohebi, Farnam , Molokhia, Mariam , Monasta, Lorenzo , Moodley, Yoshan , Moosazadeh, Mahmood , Moradi, Masoud , Moradi, Ghobad , Moradpour, Farhad , Morawska, Lídia , Velásquez, Ilais Moreno , Mossie, Tilahun Belete , Murthy, Srinivas , Musa, Kamarul Imran , Mustafa, Ghulam , Nabhan, Ashraf , Nagarajan, Ahamarshan Jayaraman , Naik, Gurudatta , Naimzada, Mukhammad David , Nangia, Vinay, Nascimento, Bruno Ramos , Naserbakht, Morteza , Ndwandwe, Duduzile , Negoi, Ionuţ , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nikbakhsh, Rajan , Ningrum, Dina Nur Anggraini , Nnaji, Chukwudi A , Nyasulu, Peter S. , Ogbo, Felix Akpojene , Oghenetega, Onome Bright , Okunga, Emmanuel , Olagunju, Andrew T , Olagunju, Tinuke O , Bali, Ahmed Omar , Onwujekwe, Obinna , Asante, Kwaku Oppong , Orpana, Heather , Otstavnov, Nikita , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakshir, Keyvan , Panda‐Jonas, Songhomitra, Park, Eun‐Kee , Patel, Sangram Kishor , Pathak, Ashish , Pati, Sanghamitra , Paulos, Kebreab , Pepito, Veincent Christian Filipino , Pham, Hai Quang , Pinheiro, Marina , Полибин, Р. В. , Polinder, Suzanne, Poustchi, Hossein, Prakash, Swayam , Pribadi, Dimas Ria Angga , Puri, Parul , Syed, Zahiruddin Quazi, Rabiee, Navid , Radfar, Amir , Rafay, Anwar, Rafiee, Ata , Rafiei, Alireza , Rahim, Fakher , Rahimi, Siavash , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Rajabpour-Sanati, Ali, Rajati, Fatemeh , Rakovac, Ivo , Ranganathan, Kavitha , Rao, Sowmya J, Rashedi, Vahid , Rastogi, Prateek , Rathi, Priya , Rawal, Lal , Rawassizadeh, Reza , Renjith, Vishnu , Renzaho, André M. N. , Resnikoff, Serge , Rezapour, Aziz, Rickard, Jennifer , Ríos-González, Carlos Miguel , Sabde, Yogesh , Saddik, Basema , Safari, Saeed , Safarpour, Hamid , Safdarian, Mahdi , Sajadi, S. Mohammad , Salamati, Payman, Salehi, Farkhonde , Zahabi, Saleh Salehi , Salem, Marwa Rashad , Salem, Hosni , Salman, Omar , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Santric-Milicevic, Milena M , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Sawyer, Susan M. , Saxena, Sonia , Schwebel, David C. , Seedat, Soraya , Senthilkumaran, Subramanian , Seyedmousavi, Seyedmojtaba , Sha, Feng , Shaahmadi, Faramarz , Shaikh, Masood Ali , Shams-Beyranvand, Mehran , Shamsizadeh, Morteza , Sharif-Alhoseini, Mahdi , Sharifi, Hamid , Sheikh, Aziz , Shigematsu, Mika, Shin, Jae Il , Shiri, Rahman , Sigfúsdóttir, Inga Dóra, Singh, Pankaj Kumar , Sinha, Dhirendra Narain , Smarandache, Catalin-Gabriel , Soleymani, Bija, Soriano, Joan B. , Soyiri, Ireneous N , Stein, Dan J. , Sufiyan, Mu’awiyyah Babale , Suleria, Hafiz Ansar Rasul , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Wogayehu, Biruk , Tamiru, Animut Tagele , Tarigan, Ingan Ukur , Tefera, Yibekal Manaye , Tekle, Merhawi Gebremedhin , Tekulu, Gebretsadkan Hintsa , Kassie, Ayenew , Bedaso, Asres , Tlaye, Kenean Getaneh , Tohidinik, Hamid Reza , Topór-Mądry, Roman , Tripathy, Jaya Prasad , Tsai, Alexander C. , Car, Lorainne Tudor , Ullah, Saif , Ullah, Irfan , Umar, Maida, Unnikrishnan, Bhaskaran , Upadhyay, Era , Valdéz, Pascual , Violante, Francesco Saverio , Waheed, Yasir , Teklay, Girmay , Werdecker, Andrea , Wiangkham, Taweewat , Wolde, Haileab Fekadu , Woldeyes, Dawit Habte , Yadav, Rajaram , Yadollahpour, Ali , Yano, Yuichiro , Yaya, Sanni , Yazdi‐Feyzabadi, Vahid , Yisma, Engida , Yoon, Seok‐Jun , Youm, Yoosik , Younis, Mustafa Z , Yousefi, Zabihollah , Yu, Yong , Yusefzadeh, Hasan, Moghadam, Telma Zahirian , Zaman, Sojib Bin , Zamanian, Maryam , Zhang, Zhi-Jiang , Zhang, Yunquan , Zodpey, Sanjay , Dandona, Lalit , Dandona, Rakhi , Hay, Simon I , Mokdad, Ali H. , Reiner, Robert C. , Sartorius, Benn , Vos, Theo , Topór‐Mądry, Roman , Zahiruddin, Quazi Syed , Dianatinasab, Mostafa , Sanati, Ali Rajabpour , Baig, Atif Amin , Kumar, Vivek , Stein, Dan J , Castaldelli-Maia, João M , Farzadfar, Farshad , Shin, Jae I L , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Belete, T , Liu, Zichen, Roberts, Nicholas L S , Abdoli, Amir , Abdollahpour, Ibrahim , Ahmed, Rushdiá , Ahmed, Muktar Beshir , Alghnam, Suliman Abdullah , Al‐Hajj, Samar , Ali, Saqib , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Amini, Saeed, Antonio, Carl Abelardo T. , Arab-Zozani, Morteza , Asaad, Malke , Balachandran, Arun , Bayati, Mohsen , Bedi, Neeraj , Behzadifar, Masoud , Benjet, Corina L. , Benseñor, Isabela M. , Bibi, Sadia , Borges, Guilherme , Boufous, Soufiane , Chatziralli, Irini , Constantin, María Magdalena , Daryani, Ahmad , Demeke, Feleke Mekonnen , Demis, Asmamaw , Forooshani, Zahra Sadat Dibaji, Duko, Bereket , Zaki, Maysaa El Sayed , Adane, Daniel, Eskandarieh, Sharareh , Yeheyis, Tomas Y. , Filip, Irina , Foroutan, Masoud , Franklin, Richard C. , Gill, Tiffany K. , Grivna, Michal , Guimarães, Rafael Alves , Gupta, Gaurav Kumar , Haghparast‐Bidgoli, Hassan , Hamidi, Samer , Haro, Josep María , Hasanzadeh, Amir , Hassanipour, Soheil , Hassankhani, Hadi , Hayat, Khezar , Hendrie, Delia V. , Holla, Ramesh , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jalilian, Farzad , Jayatilleke, Achala Upendra , Jonas, Jost B , Jungari, Suresh Banayya , Kabir, Ali , Kanchan, Tanuj , Rade, Bayew Kelkay , Khalil, Ibrahim A, Khammarnia, Mohammad , Khazaie, Habibolah , Kim, Young‐Eun , Kim, Daniel , Shivakumar, KM , Koyanagi, Ai , Kumar, Nithin , Vecchia, Carlo La , Lansingh, Van Charles , Laryea, Dennis Odai , Latifi, Arman , Lauriola, Paolo , Levi, Miriam , Lopez, Alan D , Lotufo, Paulo A. , Majeed, Azeem , Malekzadeh, Reza , Malta, Déborah Carvalho , Manjunatha, Narayana , Mansour‐Ghanaei, Fariborz , Mansournia, Mohammad Alì , Maravilla, Joemer Calderon , Melese, Addisu Dagnaw , Aschalew, Zeleke , Mengesha, Meresa Berwo , Meštrović, Tomislav , Mirică, Andreea , Mohamadi, Efat , Darwesh, Aso Mohammad , Mohammadpourhodki, Reza , Moradi‐Lakeh, Maziar , Morisaki, Naho , Morrison, Shane D. , Muluneh, Atalay Goshu , Najafi, Farid , Nayak, Vinod C , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Ota, Erika , Patton, George , Peden, Amy E. , Pereira, Jeevan , Phillips, Michael , Rabiee, Mohammad , Rawaf, Salman , Ribeiro, Ana Isabel , Ronfani, Luca , Roshandel, Gholamreza , Saad, Anas M. , Sabour, Siamak , Safari‐Faramani, Roya , Salamati, Payman, Sarker, Abdur Razzaque , Sayyah, Mehdi , Sepanlou, Sadaf Ghajarieh , Shahabi, Saeed , Siabani, Soraya , Singh, Jasvinder A. , Smith, Emma U.R. , Soheili, Amin , Soltanian, Ali Reza , Sorrie, Muluken Bekele , Stokes, Mark Andrew , Tadesse, Degena Bahrey , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Thapar, Rekha , Tran, Bach Xuan , Tran, Khanh Bao , Uthman, Olalekan Abdulrahman , Vasankari, Tommi Juhani , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Wondafrash, Dawit Zewdu , Wondmeneh, Temesgen Gebeyehu , Wondmieneh, Adam Belay , Wu, Aimin , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zandian, Hamed , Zarei, Ahmad , Zare, Fatemeh, Degenhardt, Louisa J , Dharmaratne, Samath Dhamminda , Olagunju, Andrew T , Baig, Atif Amin , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

Injury Prevention | April 24, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i96-i114

10.1136/injuryprev-2019-043494 | PMID 32332142 Get It

Background Past research in population health trends has shown that injuries form a substantial burden of population health loss. Regular updates to injury burden assessments are critical. We report Global Burden of Disease (GBD) 2017 Study estimates on morbidity and mortality for all injuries. Methods We reviewed results for injuries from the GBD 2017 study. GBD 2017 measured injury-specific mortality and years of life lost (YLLs) using the Cause of Death Ensemble model. To measure non-fatal injuries, GBD 2017 modelled injury-specific incidence and converted this to prevalence and years lived with disability (YLDs). YLLs and YLDs were summed to calculate disability-adjusted life years (DALYs). Findings In 1990, there were 4 260 493 (4 085 700 to 4 396 138) injury deaths, which increased to 4 484 722 (4 332 010 to 4 585 554) deaths in 2017, while age-standardised mortality decreased from 1079 (1073 to 1086) to 738 (730 to 745) per 100 000. In 1990, there were 354 064 302 (95% uncertainty interval: 338 174 876 to 371 610 802) new cases of injury globally, which increased to 520 710 288 (493 430 247 to 547 988 635) new cases in 2017. During this time, age-standardised incidence decreased non-significantly from 6824 (6534 to 7147) to 6763 (6412 to 7118) per 100 000. Between 1990 and 2017, age-standardised DALYs decreased from 4947 (4655 to 5233) per 100 000 to 3267 (3058 to 3505). Interpretation Injuries are an important cause of health loss globally, though mortality has declined between 1990 and 2017. Future research in injury burden should focus on prevention in high-burden populations, improving data collection and ensuring access to medical care.
Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report
Bidadi, Behzad, Watson, Andrea , Weigel, Brenda J. , Oliveira, André M. , Kirkham, Justin K. , Arndt, Carola, Oliveira, Andre, Kirkham, Justin

Mayo Clinic

Pediatric Blood & Cancer | April 20, 2020 | Volume: 67 | Issue: 6 | Pages: No page available

10.1002/pbc.28288 | PMID 32307894 Get It

AbstractInfantile myofibromatosis (IM) is characterized by solitary musculoskeletal nodules presenting during infancy but can manifest as multiple lesions with visceral involvement. Multicentric IM with visceral involvement carries a high risk of mortality and there is no consensus on treatment. We present a case of a patient with multicentric IM and pulmonary involvement who progressed on several chemotherapeutic regimens and subsequently had a complete response to sorafenib and later imatinib. This report describes the novel use of sorafenib and imatinib to treat generalized IM and the role of continued tyrosine kinase inhibitor therapy to maintain remission.
Specific Pharmacological Targeting of the Syk Kinase Activity in Platelets: A Novel, Safe Anti-Thrombotic Strategy
Delaney, Suzanne M., Sinha, Uma, Nanda, Nisha, Yan, Yibing, Hollenbach, Stan, Owen, Whyte G., André, Patrick, Pandey, Anjali , Phillips, David R.

Mayo Clinic

Blood | April 18, 2020 | Volume: 112 | Issue: 11 | Pages: 409-409

10.1182/blood.v112.11.409.409 Get It

Abstract Studies of the Syk −/− mouse have implicated spleen tyrosine kinase (Syk), a signaling protein with both kinase and scaffolding activities, in platelet signaling following engagement of GPVI and αIIbβ3 by collagen and fibrinogen, respectively. The present study was designed to determine whether specific inhibition of the kinase activity of Syk, without targeting the Syk scaffolding function, affected in vivo arterial thrombosis. In preliminary experiments, blood from wild-type and Syk−/− mice was perfused through collagen-coated capillaries under arterial shear rates to study ex vivo thrombosis. While blood from wild-type mice formed robust thrombi (37±4.7 μm3/μm2), none was observed in Syk−/− mice. Thrombi intermediate in size (16±3.9 μm3/μm2) developed in Syk+/− mice. To achieve specific pharmacological targeting of the kinase activity of Syk, P142-76, a potent (IC50 = 4 nM) and selective Syk kinase inhibitor was utilized. P142-76 was screened against a broad panel of 139 purified kinases at 50 nM. While Syk kinase was inhibited by 92%, all other kinases retained more than 70% of their activity. In washed human platelets, P142-76 inhibited convulxin (CVX)-induced phosphorylation of LAT (linker for activation of T-cells; IC50 = 111 nM) and intracellular calcium increases (IC50 = 31 nM). The GPVI/Syk-specificity of P142-76 activity was confirmed by its inability to inhibit intracellular calcium increases induced by the PAR1 thrombin receptor agonist TRAP. P142-76 also inhibited CVX-induced aggregation of both human washed platelets (IC50 = 87 nM) and platelet-rich plasma (IC50 = 2.5 μM). Considering the controversial data in respect to the participation of GPVI in arterial thrombosis in murine models, the dependence of arterial thrombosis on Syk function was studied in vivo in pigs. Cross-species activity of P142-76 was confirmed in vitro (CVX-induced PRP aggregation IC50= 350 nM; 5 μM P142-76 completely inhibited thrombosis triggered by collagen in the perfusion chamber assay). At a plasma concentration which abolished ex vivo CVX-induced but not ADP-induced pig platelet aggregation, P142-76 significantly inhibited the deposition of [111In]-labeled platelets in a carotid artery crush swine thrombosis model, without compromising primary hemostasis. % aggregation Swine (n=3) Platelet Deposition % inhibition Plasma Conc (ng/ml) Bleed Time (min) Activated Clotting Time (sec) ADP (20 μM) CVX (250 ng/ml) Control Artery 0 0 3±0.9 133±22 100 100 Treated Artery 76±6.5 1343±304 3.5±0.3 130±13 100 0 To clarify further the contribution of the kinase activity of Syk to arterial thrombosis, effects of P142-76 on human blood were evaluated in real time in the collagen-coated perfusion chamber. Low concentrations of P142-76 (0.3 μM) affected thrombus stability, while increasing concentrations (1–5 μM) delayed and then completely inhibited thrombus formation. Furthermore, P142-76 destabilized pre-formed thrombi, indicating a critical role for Syk in conferring strength to platelet-platelet interactions, i.e. αIIbβ3-mediated cohesion. Our data indicate that the kinase activity of Syk acts in arterial thrombosis through at least two distinct mechanisms. First, Syk kinase confers stability to platelet-platelet interactions downstream of αIIbβ3. Second, it initiates thrombus formation on collagen surfaces. This dual activity of the kinase activity of Syk makes it a preferred target for inhibition of arterial thrombosis, as it does not compromise primary hemostasis.
Nucleic‐Acid Mediated Expression of Cardiopoietic Markers in Human Umbilical Cord‐Derived Mesenchymal Stem Cells
Arocha, Sinibaldo Rafael Romero, Li, Mark , Arocha, Sinibaldo Romero , Singh, Raman Deep , Terzic, André , Behfar, Atta

Mayo Clinic

The FASEB Journal | April 16, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.02946 Get It

The management of patients with heart failure focuses on halting the progression of disease. To date, no therapeutic approach has been able to restore cardiac function to its original baseline state. Cell therapies, such as cardiopoietic (CP) stem cells, have shown to be promising platforms to restore cardiac function. The CP platform enhances the cardioregenerative potency of mesenchymal stem cells (MSCs). CP cells are characterized by the robust expression and nuclear translocation of cardiac transcription factors such Mesoderm Posterior Basic Helix‐Loop‐Helix Transcription Factor 1 (MESP1), early cardiac transcription factor Nkx2.5, myocyte enhancer factor 2C (Mef2C), and zinc finger‐containing transcription factor GATA4. Clinical trials using CP cells showed signs of safety and efficacy in improving cardiac function in patients with heart failure. However, the costs, time, and complexities associated with the manufacturing process have precluded the adoption of the therapy as a large‐scale clinical practice. In response, we adopted a microencapsulated‐modified‐messenger RNA (M3RNA) platform as a cost‐effective and time‐saving alternative to induce high expression of cardiopoietic markers. We hypothesized that the transfection of human umbilical cord‐derived mesenchymal stem cells (hUC‐MSCs) with M3RNA encoding mesodermal and/or cardiac transcription factor(s) will induce the expression of cardiopoietic markers (MESP1, Nkx2.5, Mef2C, and GATA4). hUC‐MSCs were transfected with M3RNA encoding Brachyury (this protein plays a key role in cardiomyocyte differentiation) and MESP1, Nkx2.5, Mef2C, and GATA4 using the transfection reagent Lipofectamine STEM. Protein expression was measured and quantified using fluorescence microscopy and flow cytometry. hUC‐MSCs transfected with M3RNA encoding mesodermal and/or cardiac transcription factor(s) demonstrated rapid protein expression at 4 hours post‐transfection that reached peak levels between 24 hours and 48 hours post‐transfection. Immunocytochemistry demonstrated similar morphology between transfected and non‐transfected cells. Thus, hUC‐MSCs can be transfected with M3RNA with high efficiency to produce rapid and predictable protein expression in vitro. We here demonstrate a simple, cost‐effective, and time‐saving approach to induce the expression of cardiopoietic markers in UC‐MSCs using M3RNA, which can serve as a highly translatable platform to circumvent many burdens associated with current strategies and development of cell‐based therapies for future clinical trials and practice. Support or Funding Information Mayo Clinic Center for Regenerative Medicine, Van Cleve Cardiac Regenerative Medicine Program, Marriott Foundation, Michael S. and Mary Sue Shannon Family, NIH NHLBI HL134664, Mayo Clinic Regenerative Sciences Post‐Baccalaureate Training Program
Epigenetic Control of Osteoblast Differentiation by Chromobox 3 (Cbx3) Protein 3
Bagheri, Leila, Thaler, Roman , Badreldin, Amr A. , Khani, Farzaneh , Deyle, David R. , Pengfei, Zan, Milbrandt, Todd A. , Dudakovic, Amel , Wijnen, André J. van , van Wijnen, Andre J , Paradise, Christopher R. , Larson, A. Noelle

Mayo Clinic

The FASEB Journal | April 15, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.00547 Get It

Skeletal development is controlled by epigenetic mechanisms that regulate chromatin compaction and suppress access to gene regulatory sequences. Post‐translational modifications in the N‐termini of histone 3 (H3), including tri‐methylated H3 lysine 9 (H3K9Me3) or lysine 27 (H3K27Me3) represent repressive chromatin marks that are recognized by a family of heterochromatin‐associated Chromobox (Cbx) proteins (i.e., Cbx1 to Cbx8). We show using RNA‐seq analysis that each of these Cbx isoforms is actively expressed in bone and osteoblasts with variable expression of distinct members (between 1 and 100 reads per million). The most prominently expressed Cbx member is Cbx3, which encodes a member of the heterochromatin protein 1 (HP1) family that interacts with H3K9me3. Cbx3 is known to be important for normal development while promoting neurogenesis, as well as renal and smooth muscle development. Therefore, we postulated that CBx3 may perform a similar role in osteoblastogenesis. We tested this hypothesis by both transient and stable knock‐down of Cbx3 by respectively siRNA or shRNA. RNA interference in MC3T3 osteoblasts effectively decreases Cbx3 mRNA levels by 2 to 5 fold, while increasing expression of bone‐related markers by RT‐qPCR (e.g., Alpl/alkaline phosphatase, Ibsp/bone sialoprotein, Bglap/osteocalcin, and Col1a1/Collagen Type I α1 chain). In addition, Cbx3 depletion increases mineral deposition as measured by Alizarin Red staining. Thus, Cbx3 normally appears to suppress osteoblastic differentiation, unlike its essential function in the neuronal differentiation. Because Cbx3 recognizes H3K9me3, we examined whether Cbx3 controls the levels of this histone mark. Loss of Cbx3 did not affect total H3K9me3 levels unless Cbx1 and Cbx5 were simultaneously depleted by siRNA. We propose that Cbx3 may suppress osteoblastogenesis by controlling select loci with H3K9me3 marks.
Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990–2017
Yadgir, Simon , Johnson, Catherine O., Aboyans, Victor, Adebayo, Oladimeji , Adedoyin, Rufus Adesoji , Afarideh, Mohsen , Alahdab, Fares , Alashi, Alaa , Alipour, Vahid, Arabloo, Jalal , Azari, Samad , Barthelemy, Celine M, Benziger, Catherine P. , Bijani, Ali , Carvalho, Félix , Durães, André Rodrigues , Esteghamati, Alireza , Farid, Talha, Farzadfar, Farshad , Fernandes, Eduarda , Gad, Mohamed M. , Hay, Simon I , Irvani, Seyed Sina Naghibi , Jürisson, Mikk , Kasaeian, Amir , Kengne, André Pascal , Khan, Abdur Rahman , Kısa, Adnan , Manafi, Navid , Manafi, Amir , Мirrakhimov, Erkin М , Mohammad, Yousef , Mokdad, Ali H. , Negoi, Ruxandra Irina , Nixon, Molly R, Patel, Shanti, Pilgrim, Thomas , Rawaf, David Laith , Rawasia, Wasiq Faraz , Rezapour, Aziz , Roever, Leonardo , Saadatagah, Seyedmohammad , Senthilkumaran, Subramanian , Sliwa, Karen, Tesfay, Berhe Etsay , Ullah, Irfan , Roth, Gregory A. , Collaborators, For the Global Burden of Disease Study 2017 Nonrheumatic Valve Disease, Sliwa, Karen , Farzadfar, Farshad , Benziger, Catherine P , Sliwa, K , Pilgrim, Thomas , Aboyans, Victor , Berman, Adam E. , Carrero, Juan Jesús , Daryani, Ahmad , Filip, Irina , Hamidi, Samer , Ilesanmi, Olayinka Stephen , Kısa, Sezer , Kolte, Dhaval , Mensah, George A. , Nguyen, Huong Lan Thi , Nguyen, Trang Huyen , Otto, Catherine M , Radfar, Amir , Rawaf, Salman , Saad, Anas M. , Tran, Bach Xuan , Vaduganathan, Muthiah , Vasankari, Tommi Juhani , Wolfe, Charles D.A. , Yonemoto, Naohiro , Collaborators, For the Global Burden of Disease Study 2017 Nonrheumatic Valve Disease, Alahdab, Fares

Mayo Clinic

Circulation | March 29, 2020 | Volume: 141 | Issue: 21 | Pages: 1670-1680

10.1161/circulationaha.119.043391 | PMID 32223336 Get It

Background: Nonrheumatic valvular diseases are common; however, no studies have estimated their global or national burden. As part of the Global Burden of Disease Study 2017, mortality, prevalence, and disability-adjusted life-years (DALYs) for calcific aortic valve disease (CAVD), degenerative mitral valve disease, and other nonrheumatic valvular diseases were estimated for 195 countries and territories from 1990 to 2017. Methods: Vital registration data, epidemiologic survey data, and administrative hospital data were used to estimate disease burden using the Global Burden of Disease Study modeling framework, which ensures comparability across locations. Geospatial statistical methods were used to estimate disease for all countries, because data on nonrheumatic valvular diseases are extremely limited for some regions of the world, such as Sub-Saharan Africa and South Asia. Results accounted for estimated level of disease severity as well as the estimated availability of valve repair or replacement procedures. DALYs and other measures of health-related burden were generated for both sexes and each 5-year age group, location, and year from 1990 to 2017. Results: Globally, CAVD and degenerative mitral valve disease caused 102 700 (95% uncertainty interval [UI], 82 700–107 900) and 35 700 (95% UI, 30 500–42 500) deaths, and 12.6 million (95% UI, 11.4 million–13.8 million) and 18.1 million (95% UI, 17.6 million–18.6 million) prevalent cases existed in 2017, respectively. A total of 2.5 million (95% UI, 2.3 million–2.8 million) DALYs were estimated as caused by nonrheumatic valvular diseases globally, representing 0.10% (95% UI, 0.09%–0.11%) of total lost health from all diseases in 2017. The number of DALYs increased for CAVD and degenerative mitral valve disease between 1990 and 2017 by 101% (95% UI, 79%–117%) and 35% (95% UI, 23%–47%), respectively. There is significant geographic variation in the prevalence, mortality rate, and overall burden of these diseases, with highest age-standardized DALY rates of CAVD estimated for high-income countries. Conclusions: These global and national estimates demonstrate that CAVD and degenerative mitral valve disease are important causes of disease burden among older adults. Efforts to clarify modifiable risk factors and improve access to valve interventions are necessary if progress is to be made toward reducing, and eventually eliminating, the burden of these highly treatable diseases.
Abstract P3-11-03: Pilot neoadjuvant study of niraparib in HER2-negative, BRCA-mutated resectable breast cancer
Liu, Minetta C. , Santa‐Maria, Cesar A. , Reeves, James E., Liem, André , Naraine, Adrianna Milillo, Nangia, Julie R. , Page, David B. , Duncan, Meghan, Shan, Ming , Tang, Yongqiang , Graham, Julie R. , Ellisen, Leif W. , Isakoff, Steven J. , Han, Hyo S , Hamilton, Erika , Irie, Hanna Y. , Santa-Maria, Cesar Augusto , Liem, Andre, Spring, Laura

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P3-11-03-P3-11-03

10.1158/1538-7445.sabcs19-p3-11-03 Get It

Abstract Background: Niraparib is a selective poly(ADP-ribose) polymerase 1/2 inhibitor that has demonstrated antitumor activity in advanced triple-negative breast cancer (TNBC) in combination with a programmed cell death 1 inhibitor, with the greatest clinical activity seen in tumors with breast cancer susceptibility gene (BRCA) mutations. Pharmacologically, niraparib has demonstrated a wide volume of distribution and high cell membrane permeability. In breast and ovarian cancer xenograft mouse models, niraparib achieved tumor exposures that were 3.3 times greater than plasma exposure. The objective of this study is to evaluate the antitumor activity of single-agent niraparib in the neoadjuvant treatment of patients with localized, human epidermal growth factor receptor 2 (HER2)-negative, BRCA-mutated breast cancer. The relative concentration of niraparib in tumor versus plasma was also assessed. Methods: Eligible patients were ≥18 years old, with HER2-negative, BRCA-mutated (germline or somatic) resectable breast cancer with a tumor size of ≥1 cm who had not received prior treatment for the current malignancy. Patients received niraparib 200 mg once daily for 2 months. At the end of 2 months, at their treating physician’s discretion, patients proceeded directly to surgery, received additional cycles of niraparib (maximum of 6 months), or received neoadjuvant chemotherapy. The primary endpoint was tumor response rate measured by magnetic resonance imaging (MRI) after 2 months of treatment. Response was defined as a ≥30% reduction in tumor volume from baseline. Secondary endpoints included tumor response rate measured by ultrasound, quantified percent change in tumor volume measured by MRI or ultrasound, pathological complete response, and safety and tolerability. Additionally, niraparib concentrations were measured in tumor and plasma samples using qualified liquid chromatography-tandem mass spectrometry. Results: Twenty-one patients were enrolled. As of June 2019, 18 patients had both an MRI and ultrasound scan at the end of month 2 and were evaluable for response. Ten patients are currently on treatment. The median age of patients was 43 years (range, 21-73). Fourteen patients had a BRCA1 mutation, 6 patients had a BRCA2 mutation, and 1 patient had both. Fifteen patients had TNBC, and 6 patients had hormone receptor-positive disease. All 18 response-evaluable patients had a clinical response after 2 months of treatment by at least one imaging modality; no patient experienced disease progression. Tumor response rate measured by MRI after 2 months of treatment was 89% (n/N = 16/18). Results measured by ultrasound were similar, with a 94% response rate at cycle 2 (n/N = 17/18). The median percent decrease in tumor volume after 2 months of treatment was 88% (range, 26-100%) and 89% (range, 23-100%) as measured by MRI and ultrasound, respectively. In the 5 samples measured thus far, niraparib concentrations in tumor biopsies after 2 months of treatment ranged from approximately 4-131-fold higher than those in corresponding plasma samples. Efficacy and tumor concentration data for all patients will be presented at the meeting. The most common (≥10%) drug-related treatment-emergent adverse events (TEAEs) of any grade were nausea, fatigue, anemia, insomnia, and decreased appetite. The only drug-related grade ≥3 toxicity in ≥10% of patients was anemia (3 patients). Three patients had a dose reduction due to a TEAE; no patient discontinued treatment due to a TEAE. Conclusion: Niraparib was well tolerated and showed promising antitumor activity in the neoadjuvant treatment of patients with localized HER2-negative, BRCA-mutated breast cancer. Niraparib achieved 4-131-fold higher concentrations in tumor than in plasma. Clinical trial information: NCT03329937. Funding: TESARO: A GSK Company (Waltham, MA, USA) sponsored the study. Citation Format: Hyo Han, Minetta C Liu, Erika Hamilton, Hanna Irie, Cesar A Santa-Maria, James Reeves, Andre Liem, Adrianna Milillo Naraine, Julie Nangia, David Page, Meghan Duncan, Ming Shan, Yongqiang Tang, Julie R Graham, Leif W Ellisen, Steven Isakoff, Laura Spring. Pilot neoadjuvant study of niraparib in HER2-negative, BRCA-mutated resectable breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-11-03.
Abstract P1-19-10: Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of
Okera, Meena , Campone, Mario , Manso, Luís , Andre, Valerie Anne Marie, Chong, Amy Lee, Antonio, Belén San , Manso Sanchez, Luis , Goetz, Matthew P. , Wildiers, Hans , Grischke, Eva‐Maria , Andre, Valerie AnneMarie, Toi, Masakazu , Sledge, George W.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P1-19-10-P1-19-10

10.1158/1538-7445.sabcs19-p1-19-10 Get It

Abstract Background: Breast cancer incidence and mortality rates are increased in patients’ older than 65 years. However, there are limited reports on age-specific efficacy, safety, and drug tolerability, particularly in elderly patients older than 75 years old. Abemaciclib demonstrated clinically meaningful progression-free survival (PFS) improvement in combination with endocrine therapy (ET) in HR+, HER2- advanced breast cancer patients in the Phase 3 studies, MONARCH 2 and 3. Here we report exploratory subgroup analyses of MONARCH 2 and 3 to provide age-specific outcomes. Methods: In MONARCH 2 (NCT02107703), patients progressing while on prior ET received abemaciclib (or placebo) plus fulvestrant; in MONARCH 3 (NCT02246621), postmenopausal women with no prior systemic therapy for recurrent or metastatic breast cancer received abemaciclib (or placebo) plus letrozole or anastrozole. Exploratory outcome analyses of MONARCH 2 and 3 studies were performed for three age groups (women aged <65, 65-74, and ≥75 years). Using pooled safety data, we performed age-specific subgroup analyses of the most common treatment-emergent adverse events (TEAEs) associated with either ET or ET plus abemaciclib. To assess the impact of age on efficacy, a subgroup analysis of PFS was performed using a Cox model for each trial independently. Results: Pooled safety data were available for 1152 patients treated in MONARCH 2 and 3 trials, including 59.7% pts <65 years, 28.7% pts between 65 and 74 years, and 11.5% pts ≥ 75 years. Of those, 768 women received abemaciclib plus ET and 384 women received placebo plus ET. The most frequent TEAE was diarrhea and the most common Grade ≥3 TEAE was neutropenia. While diarrhea (any grade) occurred with similar incidence in abemaciclib-treated patients across age groups, clinically relevant diarrhea (Grade 2/3) was higher in the elderly (<65, 39.5%; 65-74, 45.2%; ≥75, 55.4%); however, in the ≥75 group, diarrhea (Grade 2/3) incidence was also higher for placebo plus ET (<65, 6.8%; 65-74, 4.5%; ≥75, 16.0%). Similarly, nausea and decreased appetite were moderately higher (by 10-20%) in the 2 abemaciclib-treated elderly subgroups. Fatigue (any grade) was higher in the 2 abemaciclib-treated elderly subgroups (<65, 34.8%; 65-74, 48.4%; ≥75, 51.8%), while no differences were found across the 3 placebo subgroups. In contrast, the rates of Grade 3/4 neutropenia did not differ as a function of age in either the abemaciclib plus ET arm (<65, 25.8%; 65-74, 27.4%; ≥75, 18.1%) or placebo plus ET arm. For efficacy, a consistent PFS benefit was observed with abemaciclib plus ET versus placebo plus ET across all three age-specified subgroups in both studies (Table). Conclusion: Abemaciclib in combination with ET demonstrates a tolerable safety profile and consistent efficacy benefit across all age subgroups examined, supporting the use of this combination in elderly patient populations. Despite the limited number of patients in the ≥75 group with potentially confounding comorbidities, the safety data suggest that patient education and appropriate management of toxicities, including dose adjustments and use of supportive medication for gastrointestinal toxicities, could maximize the benefit of abemaciclib. Table: Age-specified PFS outcomes from MONARCH 2 and 3MONARCH 2MONARCH 3Age GroupAbemaciclib + ETPlacebo + ETHR (95% CI)P-value *Abemaciclib + ETPlacebo + ETHR (95% CI)P-value *Events/NEvents/NEvents/NEvents/N<65140/29192/1330.52 (0.40, 0.68)0.69581/18065/910.48 (0.35, 0.67)0.63465-7461/11442/600.63 (0.43, 0.94)40/10631/540.64 (0.40, 1.02)≥7521/4123/300.62 (0.34, 1.11)17/4212/200.54 (0.26, 1.13)Abbreviations: CI, confidence interval; ET, endocrine therapy; HR, hazard ratio; PFS, progression-free survival.*P-value corresponds to the interaction test between age and treatment. Citation Format: Matthew P. Goetz, Meena Okera, Hans Wildiers, Mario Campone, Eva-Maria Grischke, Luis Manso, Valerie Anne Marie Andre, Amy Lee Chong, Belen San Antonio, Masakazu Toi, George W Sledge Jr. Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-19-10.